Clinical Trials

30 enrolled

Thyroid Carcinoma, Anaplastic

NCT07419932 2026-02-19

NeoLATC

Recruiting

120 enrolled

Head & Neck

Thyroid Neoplasms

NCT02231775 2026-02-13

Dabrafenib and Trametinib Before and After Surgery in Treating Patients With Stage IIIB-C Melanoma With BRAF V600 Mutation

58 enrolled

Melanoma

NCT02693535 2026-02-13

TAPUR

Phase 1/2 Active not recruiting

4,200 enrolled

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms

NCT03225664 2026-01-16

Trametinib and Pembrolizumab in Treating Patients With Recurrent Non-small Cell Lung Cancer That Is Metastatic, Unresectable, or Locally Advanced

37 enrolled

Phase 1 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03065387 2026-01-12

Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation

93 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT03087071 2026-01-12

Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer

59 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT02910700 2025-12-17

Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma

52 enrolled

CNSDermatologic

Brain Neoplasms, Melanoma

NCT01972347 2025-12-16

Neo Combi

35 enrolled

Fever, Melanoma

NCT04116541 2025-11-21

MegaMOST

455 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT03975231 2025-11-10

Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer

Phase 1 Recruiting

6 enrolled

Thyroid Carcinoma, Anaplastic

NCT04544111 2025-10-07

PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer

19 enrolled

LymphoidOther hematologic neoplasm

Thyroid cancer, Hurthle cell, Thyroid cancer, follicular, Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenoma, Oxyphilic, Adenocarcinoma, Follicular

NCT05658640 2025-09-16

HEM-iSMART D

Phase 1/2 Recruiting

26 enrolled

Leukemia, Recurrence, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT07092670 2025-09-05

MELAFERT: Impact of Adjuvant Therapy on FERTility in Patients With Resected MELAnoma at High Risk of Relapse.

Recruiting

270 enrolled

Melanoma, Skin Neoplasms

NCT01990196 2025-08-17

Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer

45 enrolled

Genitourinary

Prostatic Neoplasms

NCT06195228 2025-08-14

A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer

Phase 4 Recruiting

800 enrolled

Advanced Thyroid Cancer Patients Who Received Target Therapy

NCT05180825 2025-08-08

PLGG - MEKTRIC

134 enrolled

Phase EARLY_PHASE1 Active not recruiting

Astrocytoma

NCT03085056 2025-07-03

Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer

13 enrolled

Thyroid Carcinoma, Anaplastic

NCT04238624 2025-07-02

Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer

16 enrolled

Phase 4 Not yet recruiting

Thyroid Neoplasms, Thyroid Carcinoma, Anaplastic

NCT07010393 2025-06-08

Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study

335 enrolled

Head & Neck

Thyroid Neoplasms

NCT05440942 2025-06-05

Combined MEK, STAT3 and PD-1 Inhibition in Metastatic Pancreatic Ductal Adenocarcinoma

28 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT06712875 2025-05-29

MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric Gliomas

Phase 1/2 Recruiting

27 enrolled

Glioma

NCT03299088 2025-05-21

Pembrolizumab and Trametinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer and KRAS Gene Mutations

15 enrolled 19 charts

MyeloidOther hematologic neoplasm

Carcinoma, Non-Small-Cell Lung

NCT06962254 2025-05-08

Imatinib and Trametinib for KRAS-mutated Solid Tumor

Phase 1 Recruiting

10 enrolled

Other solid neoplasm

Solid Tumor Cancer

NCT04487106 2025-04-22

Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome

Phase 2 Completed

21 enrolled 14 charts

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT03825289 2025-04-16

THREAD

Phase 1 Active not recruiting

25 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT06119789 2025-03-26

MATRIX-Rare

Phase 2/3 Not yet recruiting

96 enrolled

Other neoplasm

Rare Malignant Neoplasm

NCT06819605 2025-02-11

NETCAM-RCT

46 enrolled

Ameloblastoma

NCT03026517 2025-01-23

Clinical Trial of Phenformin in Combination With BRAF Inhibitor + MEK Inhibitor for Patients With BRAF-mutated Melanoma

18 enrolled

Melanoma

NCT02872259 2025-01-14

BGB324 in Combination With Pembrolizumab or Dabrafenib/Trametinib in Metastatic Melanoma

Phase 1/2 Completed

74 enrolled

Melanoma

NCT06739395 2024-12-18

Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion

300 enrolled

Other solid neoplasm

Solid Tumor

NCT06482086 2024-12-05

Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer

75 enrolled

Head & Neck

Locally Advanced Thyroid Gland Carcinoma

NCT02392871 2024-11-27

CombiRT

Phase 1/2 Completed

10 enrolled

CNSOther hematologic neoplasm

Melanoma

NCT05849662 2024-11-12

A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia

Phase 1/2 Recruiting

58 enrolled

Neurofibromatosis 1, Leukemia, Myelomonocytic, Juvenile

NCT04310397 2024-10-30

Dabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIB/C/D Melanoma

Phase 2 Terminated

4 enrolled 8 charts

Melanoma

NCT06653517 2024-10-22

NETCAM

12 enrolled

Ameloblastoma

NCT06532149 2024-08-09

EROS

Recruiting

80 enrolled

OtherThoracic

Carcinoma, Non-Small-Cell Lung, Eunuchism, Erectile Dysfunction, Sexual Dysfunction, Physiological

NCT03631953 2024-08-06

ALTREM

Phase 1 Recruiting

25 enrolled

Meningioma

NCT05159245 2024-07-15

FINPROVE

Other hematologic neoplasm

250 enrolled

Hematologic Neoplasms

NCT06456138 2024-06-13

Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC

Phase 1/2 Not yet recruiting

60 enrolled

Tumor-Agnostic

Neoplasms

NCT05435846 2024-06-11

Capmatinib Plus Trametinib for the Treatment of Metastatic Non-small Cell Lung Cancer With MET Exon 14 Skipping Mutation

Phase 1 Terminated

3 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03434262 2024-05-31

SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors

68 enrolled

CNSLymphoid

Choroid Plexus Carcinoma, Microphthalmia, Isolated, with Coloboma 5, Astrocytoma, Brain Neoplasms, Ependymoma, Glioblastoma, Glioma, Lymphoma, Follicular, Medulloblastoma, Meningioma, Neoplasms, Neoplasms, Germ Cell and Embryonal, Oligodendroglioma, Pinealoma, Recurrence, Central Nervous System Neoplasms, Neuroectodermal Tumors, Primitive, Neoplasms, Neuroepithelial, Rhabdoid Tumor, Pyloric Stenosis, Hypertrophic

NCT04967079 2024-04-23

Trametinib Plus Anlotinib in Non-G12C KRAS-Mutant NSCLC Patients

33 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03741101 2024-04-11

plexifpc

15 enrolled